Press Releases

DAY HI:
DAY LOW:
VOLUME:

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Press Releases

Date Title Format
Dec 01, 2021
Tom Riga named President and Chief Executive Officer and will join the Board of Directors effective December 31, 2021 Joe Turgeon , President and Chief Executive Officer, to retire and step down from Board of Directors HENDERSON, Nev. --(BUSINESS WIRE)--Dec. 1, 2021-- Spectrum Pharmaceuticals, Inc.
Nov 30, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 30, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the JMP Securities Hematology and Oncology Summit, a virtual presentation
Nov 11, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 11, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Jefferies London Healthcare Conference .
Nov 10, 2021
Poziotinib NDA is on track for submission in 2021 under a Fast Track designation Positive front line poziotinib data presented at ESMO Congress 2021 from Cohort 4 of the ZENITH20 clinical trial Preclinical data presented at 2021 AACR-NCI-EORTC (Triple) conference demonstrated the synergistic impact
Nov 03, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Nov. 3, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the third quarter 2021 financial results and provide a corporate
Oct 07, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Oct. 7, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced the presentation of preclinical data demonstrating the synergistic impact of poziotinib when combined with KRAS
Sep 22, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 22, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that management will participate in the 2021 Cantor Virtual Global Healthcare Conference .
Sep 18, 2021
Early data from Cohort 4 of the ongoing ZENITH20 clinical trial shows ORR of 44% in 48 first-line patients treated with 16mg of poziotinib once daily HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 18, 2021-- Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and
Sep 13, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Sep. 13, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a late-breaking presentation of early poziotinib efficacy and safety data in first-line patients with non-small
Aug 12, 2021
Submission of poziotinib NDA on track for later in 2021 under a Fast Track designation The company is requesting a meeting with the FDA to clarify the remediation timelines regarding the Complete Response Letter (CRL) for ROLONTIS ® (eflapegrastim) Management to host webcast and conference call
Aug 06, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 6, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the
Aug 05, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Aug. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the second quarter 2021 financial results and provide a corporate
Jun 04, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 4, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented an e-poster on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.
Jun 01, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Jun. 1, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced that the U.S. Food and Drug Administration (FDA) is “on site” for the ROLONTIS® (eflapegrastim) manufacturing
May 28, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--May 28, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on poziotinib CNS activity in patients with NSCLC with EGFR or HER2 exon 20 mutations.
May 27, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--May 27, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, announced today that management will present an overview of the company's business strategy and development-stage programs at
May 13, 2021
Poziotinib NDA on track for 2021 submission New poziotinib twice daily dosing (BID) data presented at AACR demonstrated improved anti-tumor activity and better tolerance FDA pre-approval inspection at the ROLONTIS ® manufacturing facility scheduled for May 2021 Management to host webcast and
May 06, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--May 6, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced it will host a conference call to discuss the first quarter 2021 financial results and provide a corporate update
Apr 10, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 10, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented a data update on the safety and tolerability of twice daily (BID) administered poziotinib in NSCLC patients
Apr 05, 2021
HENDERSON, Nev. --(BUSINESS WIRE)--Apr. 5, 2021-- Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today announced a poster presentation on safety and tolerability of twice daily administered poziotinib in patients with EGFR or
Displaying 1 - 20 of 855